Evidence map›Paper›PMID 35596098›Full record

SynthesisThe European journal of health economics : HEPAC : health economics in prevention and care2023

Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease.

B Rodríguez-Sánchez, S Daugbjerg, L M Peña-Longobardo, J Oliva-Moreno, I Aranda-Reneo, A Cicchetti, J López-Bastida

Abstract readSystematic Review
In one paragraph

Synthesis in The European journal of health economics : HEPAC : health economics in prevention and care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Cost-effectiveness analysis of the MYO ArmbandJournal of neuroengineering and rehabilitation · 2025
    Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Letter to the Editor: Lazzaro responds to Rodríguez‑Sánchez et al.The European journal of health economics : HEPAC : health economics in prevention and care · 2023
    Article
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

B Rodríguez-SánchezDepartment of Applied Economics, Public Economics and Political Economy, University Complutense of Madrid, Pl. Menéndez Pelayo 4, 28040, Madrid, Spain.ORCID http://orcid.org/0000-0002-6146-068X
S DaugbjergGraduate School of Health Economics and Management (Alta Scuola Di Economia E Management Dei Sistemi Sanitari), Universitá Cattolica del Sacro Cuore, Rome, Italy.
L M Peña-LongobardoEconomic Analysis and Finance Department, Faculty of Law and Social Sciences, University of Castilla-La Mancha, 45071, Toledo, Spain.ORCID http://orcid.org/0000-0001-7224-2189
J Oliva-MorenoEconomic Analysis and Finance Department, Faculty of Law and Social Sciences, University of Castilla-La Mancha, 45071, Toledo, Spain.ORCID http://orcid.org/0000-0002-8997-0307
I Aranda-ReneoEconomic Analysis and Finance Department, Faculty of Social Sciences, University of Castilla-La Mancha, Avda. Real Fábrica de Seda s/n, 45600, Talavera de la Reina, Toledo, Spain. isaac.aranda@uclm.es.ORCID http://orcid.org/0000-0002-7311-2615
A CicchettiGraduate School of Health Economics and Management (Alta Scuola Di Economia E Management Dei Sistemi Sanitari), Universitá Cattolica del Sacro Cuore, Rome, Italy.ORCID http://orcid.org/0000-0002-4633-9195
J López-BastidaFaculty of Health Sciences, Universidad Castilla-La Mancha, 45600, Talavera de la Reina, Toledo, Spain.

Funding

h2020 european research council 779312
6 · The paper itself

Abstract

backgroundMultiple sclerosis imposes a heavy burden on the person who suffers from it and on the relatives, due to the caregiving load involved. The objective was to analyse whether the inclusion of social costs in economic evaluations of multiple sclerosis-related interventions changed results and/or conclusions.

methodsA systematic review was launched using Medline and the Cost-Effectiveness Analysis Registry of Tufts University (2000-2019). Included studies should: (1) be an original study published in a scientific journal, (2) be an economic evaluation of any multiple sclerosis-related intervention, (3) include productivity losses and/or informal care costs (social costs), (4) be written in English, (5) use quality-adjusted life years as outcome, and (6) separate the results according to the perspective applied.

resultsTwenty-nine articles were selected, resulting in 67 economic evaluation estimations. Social costs were included in 47% of the studies. Productivity losses were assessed in 90% of the estimations (the human capital approach was the most frequently used method), whereas informal care costs were included in nearly two-thirds of the estimations (applying the opportunity and the replacement-cost methods equally). The inclusion of social costs modified the figures for incremental costs in 15 estimations, leading to a change in the conclusions in 10 estimations, 6 of them changing from not recommended from the healthcare perspective to implemented from the societal perspective. The inclusion of social costs also altered the results from cost-effective to dominant in five additional estimations.

conclusionsThe inclusion of social costs affected the results/conclusions in multiple sclerosis-related interventions, helping to identify the most appropriate interventions for reducing its economic burden from a broader perspective.

Indexed as

Multiple SclerosisCost-Benefit AnalysisCost-Effectiveness AnalysisDelivery of Health CareHumansPatient CareCost-effectivenessCost-utilityEconomic evaluationHealth technology assessmentInformal careMultiple sclerosisProductivity lossesSocial costsSocietal perspective

Identifiers

PMID35596098
PMCPMC9985586

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.